Humatrope (Somatropin)

Humatrope is indicated for several growth‑related disorders where endogenous growth hormone production is insufficient or where growth promotion is clinically warranted.

• Growth hormone deficiency in children and adults.
• Turner syndrome associated short stature.
• Chronic renal insufficiency affecting growth.
• Prader‑Willi syndrome with growth impairment.
• Idiopathic short stature when other causes are excluded.
• Growth failure secondary to small‑for‑gestational‑age birth.

• Somatropin in Humatrope is a recombinant form of human growth hormone that binds to growth‑hormone receptors on target cells, primarily in liver and peripheral tissues. Receptor activation triggers the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling cascade, leading to increased transcription of insulin‑like growth factor‑1 (IGF‑1) and other downstream mediators that promote cellular proliferation, protein synthesis, and linear growth.

Humatrope may cause a range of adverse reactions, most of which are mild and transient, while rarer events can be serious.

Common

• Pain, redness, swelling, or bruising at the injection site, usually resolving within a few days.
• Persistent or throbbing headache that may be mild to moderate in intensity.
• Musculoskeletal discomfort such as joint stiffness, muscle aches, or mild arthralgia.

Serious

• Intracranial hypertension presenting with persistent headache, visual disturbances, nausea, or papilledema, requiring immediate medical evaluation.
• Slipped epiphysis (growth‑plate injury) leading to acute bone pain, limited mobility, and potential growth disturbances.
• Severe hypersensitivity reactions, including widespread rash, urticaria, angioedema, or anaphylaxis, which may necessitate emergency treatment.

Before initiating Humatrope, clinicians should evaluate several safety considerations to minimize risks and ensure appropriate use.

• Assess for active malignancies, as growth hormone may accelerate tumor growth.
• Screen for uncontrolled diabetes or impaired glucose tolerance; monitor blood glucose during therapy.
• Evaluate for intracranial hypertension symptoms, especially in patients with prior head trauma or hydrocephalus.
• Review history of hypersensitivity to somatropin or any excipients.
• Consider potential for slipped epiphysis in rapidly growing children; monitor growth plates regularly.
• Use caution in patients with severe renal or hepatic impairment, adjusting monitoring accordingly.

Humatrope can interact with other medicines or substances that affect its efficacy or safety profile; clinicians should review a patient’s full medication list.

Avoid

• Concomitant high‑dose glucocorticoids may blunt growth‑hormone’s anabolic effects and lower IGF‑1.
• Antidiabetic drugs such as sulfonylureas can mask the hyperglycemia that growth hormone may cause.
• Intravenous insulin infusions without frequent glucose checks increase risk of severe hypoglycemia with growth hormone.

Use with caution

• Oral estrogen may reduce IGF‑1 response to somatropin, possibly requiring dose adjustment.
• Thyroid hormone replacement is needed for optimal response; untreated hypothyroidism can blunt therapy.
• Diuretics that affect fluid balance can worsen edema when used with growth hormone.